News
In the summer of 2020, shortly after the US Food and Drug Administration issued a negative Complete Response Letter to AbbVie and Molecular Partners, rejecting…
Read More
Amydis is developing novel small-molecule contrast agents that aim to enable the direct visualization of central nervous system (CNS) disease-related biomarkers in the retina. The…
Read More
A number of companies are developing drug treatments for geographic atrophy, the result of advanced dry age-related macular degeneration (AMD), for which no approved treatments…
Read More
In 2018, 4D Molecular Therapeutics announced it was expanding its 2015 research agreement with Roche to develop and commercialize multiple ophthalmology products. This summer, things…
Read More
Up until a few weeks ago, 2021 had been an up-and-down year for retinal prosthesis maker Second Sight Medical Products, but it recently got a…
Read More
South Korea-based Samsung Bioepis Co. has gained another leg up in the race for an anti-VEGF biosimilar to treat retinal diseases in the lucrative US…
Read More
The novel platform Clearside Biomedical is developing for delivering drugs to the back of the eye has taken two steps forward in recent weeks, with…
Read MoreHeru, developer of an artificial intelligence-powered vision diagnostics and augmentation software platform, gave its development program a boost when it closed a Series A financing…
Read More
Weeks after receiving Food and Drug Administration approval for its complement factor 3 (C3) inhibitor pegcetacoplan, now known as Empaveli, to treat adults who have…
Read More
Oxurion NV, the Brussels-based biopharmaceutical company formerly known as ThromboGenics, entered into a capital commitment agreement of up to $36 million (€30 million) with Negma…
Read More
Money is pouring into digital health at a record clip – $6.7 billion in the first quarter this year, the investment firm Rock Health reports.…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")